- Home
- LUCY vs XAIR Comparison
LUCY vs XAIR Comparison
Compare LUCY & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | XAIR |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Ophthalmic Goods | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.4M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | LUCY | XAIR |
|---|---|---|
| Price | $1.03 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 77.0K | ★ 320.4K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,705,000.00 |
| Revenue This Year | $175.92 | $122.00 |
| Revenue Next Year | $205.56 | $58.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.95 | $0.15 |
| 52 Week High | $3.54 | $3.78 |
Technical Indicators
Market Signals| Indicator | LUCY | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 38.41 |
| Support Level | $1.01 | $0.43 |
| Resistance Level | $1.17 | $0.82 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 25.02 | 36.87 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.